Receptos Company Profile (NASDAQ:RCPT)

About Receptos (NASDAQ:RCPT)

Receptos logoReceptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. It is developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn's Disease (CD). It is developing its second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which it has been granted Orphan drug designation. Its research efforts include a preclinical program developing oral, small molecule, positive allosteric modulators (PAMs) of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of Type 2 Diabetes.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RCPT
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $226.05
  • 200 Day Moving Avg: $174.22
  • 52 Week Range: $46.94 - $232.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -28.25
  • P/E Growth: 0.00
  • Return on Equity: -44.89%
  • Return on Assets: -41.50%
  • Average Volume: 1.16 million shs.
Frequently Asked Questions for Receptos (NASDAQ:RCPT)

What is Receptos' stock symbol?

Receptos trades on the NASDAQ under the ticker symbol "RCPT."

How were Receptos' earnings last quarter?

Receptos Inc (NASDAQ:RCPT) issued its earnings results on Tuesday, May, 5th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.09) by $0.20. View Receptos' Earnings History.

Who are some of Receptos' key competitors?

How do I buy Receptos stock?

Shares of Receptos can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Receptos' stock price today?

One share of Receptos stock can currently be purchased for approximately $231.96.

MarketBeat Community Rating for Receptos (NASDAQ RCPT)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Receptos and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Receptos (NASDAQ:RCPT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Receptos (NASDAQ:RCPT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/26/2015WedbushDowngradeOutperform -> Neutral$232.00N/AView Rating Details
(Data available from 7/23/2015 forward)


Earnings History for Receptos (NASDAQ:RCPT)
Earnings by Quarter for Receptos (NASDAQ:RCPT)
Earnings History by Quarter for Receptos (NASDAQ RCPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2015Q115($1.09)($1.29)$5.10 millionViewN/AView Earnings Details
3/3/2015Q414($1.19)($1.32)$2.06 millionViewN/AView Earnings Details
11/4/2014Q314($0.96)($1.19)$1.00 million$3.45 millionViewN/AView Earnings Details
8/12/2014Q214($0.85)($1.04)$1.28 million$1.10 millionViewN/AView Earnings Details
5/12/2014Q114($0.84)($1.01)$0.49 million$1.40 millionViewN/AView Earnings Details
3/5/2014($0.86)($0.86)$1.16 million$0.77 millionViewN/AView Earnings Details
10/30/2013Q313($0.61)($0.88)$1.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Receptos (NASDAQ:RCPT)
Current Year EPS Consensus Estimate: $-7.14 EPS
Next Year EPS Consensus Estimate: $-8.21 EPS


Dividend History for Receptos (NASDAQ:RCPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Receptos (NASDAQ:RCPT)
Insider Trades by Quarter for Receptos (NASDAQ:RCPT)
Insider Trades by Quarter for Receptos (NASDAQ:RCPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2015S. Edward TorresDirectorSell220,000$178.99$39,377,800.00View SEC Filing  
2/23/2015S. Edward TorresDirectorSell47,906$128.20$6,141,549.20View SEC Filing  
11/11/2014Faheem HasnainCEOSell200,000$109.47$21,894,000.00View SEC Filing  
11/11/2014Sheila GujrathiInsiderSell30,000$108.99$3,269,700.00View SEC Filing  
11/10/2014Chrysa MineoSVPSell30,000$109.73$3,291,900.00View SEC Filing  
11/10/2014Faheem HasnainCEOSell136,795$109.69$15,005,043.55View SEC Filing  
11/10/2014Marcus F BoehmCTOSell40,454$109.91$4,446,299.14View SEC Filing  
9/23/2014S. Edward TorresDirectorSell100,000$61.36$6,136,000.00View SEC Filing  
9/22/2014S. Edward TorresDirectorSell14,318$63.08$903,179.44View SEC Filing  
9/22/2014Sheila GujrathiInsiderSell30,000$61.45$1,843,500.00View SEC Filing  
9/19/2014S. Edward TorresDirectorSell169,570$62.55$10,606,603.50View SEC Filing  
9/18/2014S. Edward TorresDirectorSell91,513$62.77$5,744,271.01View SEC Filing  
9/17/2014David A HinkleCAOSell2,000$64.82$129,640.00View SEC Filing  
9/17/2014S. Edward TorresDirectorSell38,917$63.67$2,477,845.39View SEC Filing  
9/16/2014Graham K CooperCFOSell50,000$61.30$3,065,000.00View SEC Filing  
9/2/2014David A HinkleCAOSell2,000$52.80$105,600.00View SEC Filing  
8/13/2014David A HinkleCAOSell3,000$42.69$128,070.00View SEC Filing  
8/13/2014S. Edward TorresDirectorSell200,000$43.24$8,648,000.00View SEC Filing  
5/29/2014Kristina BurowDirectorSell153,698$29.74$4,570,978.52View SEC Filing  
5/21/2014S. Edward TorresDirectorSell424,068$25.26$10,711,957.68View SEC Filing  
5/15/2014S. Edward TorresDirectorSell90,075$27.37$2,465,352.75View SEC Filing  
5/14/2014Kristina BurowDirectorSell45,381$29.66$1,346,000.46View SEC Filing  
1/3/2014William RastetterDirectorSell37,359$30.85$1,152,525.15View SEC Filing  
1/2/2014William RastetterDirectorSell27,581$30.29$835,428.49View SEC Filing  
12/6/2013Amir NashatDirectorSell170,000$26.70$4,539,000.00View SEC Filing  
12/5/2013William RastetterDirectorSell500,000$27.63$13,815,000.00View SEC Filing  
11/18/2013Ventures Fund 2007 Flagshipmajor shareholderSell230,787$24.75$5,711,978.25View SEC Filing  
11/15/2013Amir NashatDirectorSell169,315$24.96$4,226,102.40View SEC Filing  
5/14/2013Amir NashatDirectorBuy151,343$14.00$2,118,802.00View SEC Filing  
5/14/2013Ventures Fund 2007 L FlagshipMajor ShareholderBuy107,142$14.00$1,499,988.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Receptos (NASDAQ:RCPT)
Latest Headlines for Receptos (NASDAQ:RCPT)
DateHeadline logoWhat Gilead Could Learn From Celgene - Seeking Alpha - July 8 at 1:59 PM logoLook Under The Hood: IWC Has 17% Upside - June 19 at 10:07 AM logoAnalysts Predict 20% Gains Ahead For IWC - June 1 at 9:03 PM logo3 Large-Cap Stocks for the Long Term - May 30 at 7:10 PM
News IconUPDATE 1-Celgene's multiple sclerosis drug succeeds in late-stage trial - May 23 at 9:40 AM logoCelgene: Fears Over Revlimid Create A Buying Opportunity - May 11 at 7:57 PM logoThe Implied Analyst 12-Month Target For IWC - May 8 at 11:51 AM logoCelgene Is A Must-Own Stock - April 26 at 5:49 PM logoSurprising Analyst 12-Month Target For IWC - April 12 at 6:35 PM logoSea Turtle Scientist Hunts for China’s First Blockbuster - April 7 at 12:12 PM logoCelgene Acquired Receptos as M&As Continue to Drive the Market - April 7 at 12:12 PM logoCelgene Corporation -- Moody's lowers Celgene to Baa2 stable; rates new notes Baa2 - April 7 at 12:12 PM logoCelgene's Deal-Making Magic Lifts Receptos 20% in July - April 7 at 12:12 PM logoCelgene Corporation Topped Last Week’s High-Grade Bond Issuance - April 7 at 12:12 PM logoBluebird, Pacira Pharmaceuticals Excite Life Science Investors - April 7 at 12:12 PM logo5 Things Celgene Corporation Wants You to Know - April 7 at 12:12 PM logoCelgene Vs. Gilead: Vetting for the Best Biopharma - April 7 at 12:12 PM logoOpko Health Reports Weak 2Q15 Results - April 7 at 12:12 PM logo2 Questions Investors Need to Ask About Biogen's Latest Deal - April 7 at 12:12 PM logoIMNP: Clinical Sites to Open for BP Trial in the U.S.… - April 7 at 12:12 PM logoMultiple Abstracts Concerning MIS416 Mechanism of Action Accepted for Presentation at Upcoming American Academy of Neurologists Meeting - March 7 at 7:20 PM logoInsider Selling Picks Up as Market Volatility Jumps - January 9 at 7:27 AM logoBiotech Bull Markets and Billion-Dollar Valuations - January 9 at 7:27 AM logoHuge Biotech Trade Highlights Insider Selling as Market Hits Record Highs - January 9 at 7:27 AM logoCelgene to buy Receptos for $7.2 bln - January 9 at 7:27 AM logoCelgene will buy drug developer Receptos for $7.32 billion - January 9 at 7:27 AM logoCelgene to buy Receptos for $7.2 bln; gains promising drug - January 9 at 7:27 AM logoIs Celgene Transforming Itself With Mergers and Pacts? - January 9 at 7:27 AM logoBioniz Therapeutics Appoints Paul Frohna M.D., Ph.D., Pharm. D., as Senior Vice President of Clinical Development - December 20 at 7:10 PM logoIs This a Potential $7 Billion Waste for Celgene Corporation? - January 8 at 8:19 AM logoRECEPTOS, INC. Files SEC form 10-Q, Quarterly Report - July 30 at 6:12 AM logoMorgan Stanley Raises Price Target On Celgene, Still Highlights Several Risks - July 27 at 12:24 PM



Receptos (RCPT) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by Staff